Related Experiment Video
Updated: Mar 14, 2026
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
Targeting Gliomas: Can a New Alkylating Hybrid Compound Make a Difference?
Rui Pinheiro1, Cláudia Braga1, Gisela Santos1
1Research Institute for Medicines (iMed.ULisboa), ‡Department of Biochemistry and Human Biology, §Department of Pharmaceutical Chemistry and Therapeutics, and ∥Department of Toxicological and Bromatological Sciences, Faculty of Pharmacy, Universidade de Lisboa , Avenida Professor Gama Pinto, 1649-003 Lisbon, Portugal.
A new hybrid compound (HYBCOM) combining temozolomide and valproic acid shows improved glioblastoma treatment efficacy. HYBCOM reduces tumor cell viability and migration while avoiding drug resistance, offering promise over temozolomide alone.
Area of Science:
- Oncology
- Pharmacology
- Drug Discovery
Background:
- Glioblastoma (GBM) is an aggressive brain tumor with limited treatment options.
- Temozolomide (TMZ) is a standard chemotherapy but faces significant resistance in GBM.
- Hybrid compounds offer a novel strategy to overcome therapeutic challenges in GBM.
Purpose of the Study:
- To synthesize and evaluate a novel hybrid compound (HYBCOM) combining a TMZ analogue and valproic acid.
- To compare the chemotherapeutic efficacy of HYBCOM against TMZ in glioblastoma models.
- To investigate HYBCOM's mechanisms of action, including cytotoxicity, cellular effects, and drug resistance modulation.
Main Methods:
- Synthesis of a hybrid compound (HYBCOM) by covalently linking a TMZ analogue and valproic acid.
- In vitro evaluation of HYBCOM's effects on GL261 glioma cells and normal astrocytes.
- Assessment of cell viability, proliferation, morphology, migration, autophagy, and drug resistance protein expression.
Main Results:
- HYBCOM significantly decreased viability and proliferation of GL261 glioma cells more effectively than TMZ.
- HYBCOM demonstrated better targeting of tumor cells compared to normal astrocytes.
- HYBCOM induced cellular changes, impaired migration, enhanced autophagy, and crucially, did not increase drug resistance protein expression.
Conclusions:
- The novel hybrid compound HYBCOM exhibits superior chemotherapeutic potential over TMZ for glioblastoma.
- HYBCOM's ability to overcome drug resistance mechanisms presents a significant advantage.
- Further studies are warranted to validate HYBCOM's efficacy in preclinical models and clinical trials for GBM patients.
